Blue Biotechnology 2018
DOI: 10.1002/9783527801718.ch19
|View full text |Cite
|
Sign up to set email alerts
|

Bioactive Marine Molecules and Derivatives with Biopharmaceutical Potential

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
9
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
2
2
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(9 citation statements)
references
References 94 publications
0
9
0
Order By: Relevance
“…Where required, low resolution ESI tandem MS was performed on a Bruker amaZon SL ion trap via syringe infusion or by injection into a constant flow stream with a rheodyne valve and an Alltech HPLC pump (mobile phase methanol, flow rate 0.3 mL min -1 ) connected to an Apollo II ESI MTP ion source in positive ion mode. Tandem mass spectra of the [M+H] + parent ion were obtained manually up to MS 5 (depending on sensitivity). Spectra were acquired in positive ion mode using a 1–4 Da isolation window, with the excitation amplitude manually optimized for each spectrum to have the selected mass at ~10% of the height of the largest fragment.…”
Section: Experimental Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Where required, low resolution ESI tandem MS was performed on a Bruker amaZon SL ion trap via syringe infusion or by injection into a constant flow stream with a rheodyne valve and an Alltech HPLC pump (mobile phase methanol, flow rate 0.3 mL min -1 ) connected to an Apollo II ESI MTP ion source in positive ion mode. Tandem mass spectra of the [M+H] + parent ion were obtained manually up to MS 5 (depending on sensitivity). Spectra were acquired in positive ion mode using a 1–4 Da isolation window, with the excitation amplitude manually optimized for each spectrum to have the selected mass at ~10% of the height of the largest fragment.…”
Section: Experimental Methodsmentioning
confidence: 99%
“…Marine ecosystems have long been a rich source of bioactive natural products, in the search for interesting molecules and novel therapeutic agents. 15 Many interesting and structurally diverse secondary metabolites have been isolated from marine sources and characterised over the last 70 years. 69 Yet the first ‘drugs from the sea’ were only approved in the early 2000s: the cone snail peptide ziconotide (ω-conotoxin MVIIA) in 2004 to alleviate chronic pain, 10 and sea squirt metabolite trabectedin in 2007 for treatment of soft-tissue sarcoma.…”
Section: Introductionmentioning
confidence: 99%
“…Nevertheless, these enzymes are not enough to respond to the new technological challenges that appear each day [157]. [158]. The market for industrial enzymes is growing every year and the exploitation of extremozymes is a huge and mostly unexplored resource [159].…”
Section: Biotechnological Applications Of Piezophilesmentioning
confidence: 99%
“…Additionally, many piezophilic bacteria contain omega 3-PUFAs associated with their cell membrane, which are precursors to hormones and hormonelike molecules in many animals. Consequently, it could be used for hypertriglyceridemia diseases and clinical studies for this purpose have already been approved [158].…”
Section: Biotechnological Applications Of Piezophilesmentioning
confidence: 99%
“…1 Marine ecosystems have long been a rich source of bioactive natural products in the search for interesting molecules and novel therapeutic agents. 2–6 Many interesting and structurally diverse secondary metabolites have been isolated from marine sources over the last 70 years. 7–10 In addition, the preclinical pharmacology of seventy-five compounds isolated from marine organisms have been reported to have biological activities.…”
Section: Introductionmentioning
confidence: 99%